Overview

Study of Optimizing Neoadjuvant Regimens in Subtypes of Breast Cancer

Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
There are no standard neodjuvant regimens adapted according to the different subtypes of breast cancer. This is a phase 2, randomized study to evaluate several regimens in different subtypes of breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Chinese Academy of Medical Sciences
Treatments:
Albumin-Bound Paclitaxel
Carboplatin
Epirubicin
Paclitaxel